Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on WYG PLC. We currently have 48 research reports from 4 professional analysts.
|30Jan17 13:08||RNS||Notification of Major Interest in Shares|
|30Jan17 07:00||RNS||Directorate Change|
|24Jan17 11:31||RNS||Notification of Major Interest in Shares|
|24Jan17 11:23||RNS||Total Voting Rights|
|09Jan17 10:07||RNS||Notification of Major Interest in Shares|
|05Jan17 17:02||RNS||Notification of Major Interest in Shares|
|09Dec16 15:12||RNS||Director/PDMR Shareholding|
Frequency of research reports
Research reports on
New orders send positive signals
31 Jan 17
The latest contract win announcements continue the order momentum seen at the time of H117 results. The significance of new international workflow will serve to underpin our expectation of an improving overseas contribution and, at the same time, provide post-Brexit reassurance for investors. We expect this will translate to further share price progress.
N+1 Singer - WYG - EU-financed contract wins support improving outlook
26 Jan 17
WYG has announced a number of significant new EU-financed contract awards. The contracts are worth €17m to WYG over the next four years. It is highly encouraging that WYG’s international businesses continue to access significant EU funds, particularly under accession assistance programmes. The Group continues to see a high quality pipeline of commercially attractive opportunities being tendered and current year forecasts look well underpinned (more than 70% cover). In our view, the recent recovery in the Group’s share price is fully justified. The shares still trade at a discount to the peer group (Cal. ’17 EV/EBITDA multiple of 6.5x vs. 7.2x) which we would expect to close over time.
N+1 Singer - Morning Song 26-01-2017
26 Jan 17
Brewin Dolphin Holdings (BRW LN) Core FuM +3.4% on positive investment performance | Brooks Macdonald Group (BRK LN) +4.6% FuM: solid net inflows, benefiting from positive performance | EMIS Group (EMIS LN) In line trading update, market still challenging | Findel (FDL LN) Positive momentum and outlook in Express Gifts | Mobile Streams (MOS LN) H1 trading update – India scaling commences | Renishaw (RSW LN) Interim results and guidance in line with expectations | WYG (WYG LN) EU-financed contract wins support improving outlook
Order books driving momentum
19 Dec 16
H117 results showed good progress with unchanged full year guidance. Rising order books and confident management messaging support expectations of a good H2 profit uplift and healthy momentum going into FY18. These prospects are not fully reflected in WYG’s rating in our view.
N+1 Singer - WYG - Order book strength underpins FY expectations
01 Dec 16
WYG’s interims confirm a period of strong progress in the UK and MENA as well as significant growth in the order book. Market conditions in the UK look to be supportive, with further positive measures announced in the Autumn Statement. Meanwhile, WYG’s international businesses continue to access significant EU funds, particularly under accession assistance programmes. Current year forecasts look well underpinned (70% cover) and we see continued scope for organic growth to be augmented by earnings enhancing acquisitions. In our view, recent share price weakness (P/E rating of just 8x) is unjustified and overlooks WYG’s unique offering and growth ambitions.
N+1 Singer - Morning Song 01-12-2016
01 Dec 16
Blackstone/GSO Loan Financing (BGLF LN) CLO refinancing outlook | Clipper Logistics (CLG LN) Interims highlight further significant growth | Grainger (GRI LN) Final results in line, further progress on PRS investment pipeline | Vernalis (VER LN) AGM statement in line with expectations | WYG (WYG LN) Order book strength underpins FY expectations
20 Feb 17
Hayward Tyler Group* (HAYT): Trading update and financial position (CORP) | Petra Diamonds (PDL): Interim results (BUY) | Gemfields* (GEM): Interim results (CORP) | Premaitha Health* (NIPT): Middle East momentum (CORP) | Sound Energy (SOU): Acquisition update and TE-8 well spud (HOLD) | Proactis* (PHD): Interim trading on track (CORP) | 7digital* (7DIG): Automotive contract win (CORP)
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
N+1 Singer - Small-cap quantitative research - New quality style screen + 11 quality focus stocks
09 Feb 17
We introduce our fourth and final style screen representing “quality”. This screens for stocks with the best combination of high returns on capital/equity, EBIT margins and operating cash-flow conversion rates. These criteria should help us monitor how strong underlying returns translate into share price performance over time and under varying market conditions. The screen selects the “best” 25 stocks from our universe of just over 500 stocks and, as usual, we focus on a shorter list of stocks we cover or otherwise know and believe to be particularly interesting. We provide brief investment summaries on these focus stocks on pages 4 – 9. We will monitor performance and refresh the screen in approximately 3-4 months time.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals